Fate Therapeutics INC Form 4 insider transactions

Cindy Tahl, See Remarks of Fate Therapeutics Inc, sold 38,800 shares of common stock on August 4, 2026 for $2.46 per share.

Bahram Valamehr, President and CEO and a Director of Fate Therapeutics Inc, sold 43,947 shares of common stock on August 4, 2026 for $2.46 per share.

Redmile Group, LLC reported the acquisition of 87,900 stock options in Fate Therapeutics, Inc. as compensation for board service.

Director Michael Lee was granted 87,900 stock options in Fate Therapeutics, which are held for the benefit of Redmile Group.

Yuan Xu, a Director at Fate Therapeutics, received a grant of stock options.

Director Karin Jooss of Fate Therapeutics was granted stock options as part of the company's director compensation policy.

Robert S. Epstein, a Director at Fate Therapeutics, Inc., received a grant of stock options.

Shefali Agarwal, a Director at Fate Therapeutics, received a grant of stock options as part of the company's annual equity awards for non-employee directors.

Matt Abernethy, a Director at Fate Therapeutics, received a grant of stock options.

Fate Therapeutics reports a stock option grant to Director William H. Rastetter.

Fate Therapeutics reports a stock option grant to Director Laura Hamill, with vesting over three years.

Fate Therapeutics reports a "sell-to-cover" transaction by Chief Legal and Compliance Officer Cindy Tahl to satisfy tax withholding obligations upon the vesting of performance-based RSUs.

Fate Therapeutics reports an insider, Bahram Valamehr, sold 28,946 shares of common stock to cover tax withholding obligations related to RSU vesting.

Fate Therapeutics officer Cindy Tahl acquired shares through stock options on May 6, 2026, as detailed in a Form 4 filing.

Director Robert S. Epstein acquired 25,000 shares of Fate Therapeutics common stock on May 5, 2026, at a price of $1.69 per share.

William H. Rastetter, a Director at Fate Therapeutics, Inc., has acquired 25,000 shares of common stock through the exercise of a stock option.

Redmile Group filed an amendment to a Form 4 to correct an administrative error regarding the reference price of swap agreements involving Fate Therapeutics stock.

Redmile Group, LLC has completed an internal reorganization of its holdings in Fate Therapeutics Inc, transferring over 8.9 million shares and various derivative securities to subsidiary entities.

Cindy Tahl, Chief Legal and Compliance Officer of Fate Therapeutics, was granted 100,000 restricted stock units and options to purchase 400,000 shares of common stock.

FATE Therapeutics' Chief Financial Officer, Kamal Adawi, was granted 25,000 restricted stock units and options to purchase 75,000 shares of common stock.

Fate Therapeutics' President and CEO, Bahram Valamehr, received an award of 335,000 restricted stock units and 1,300,000 stock options.

Cindy Tahl, Chief Legal and Compliance Officer at Fate Therapeutics, sold 10,589 shares of common stock to cover tax withholding obligations related to RSU vesting.

FATE Therapeutics President and CEO, Bahram Valamehr, sold 5,190 shares of common stock to cover tax withholding obligations related to RSU vesting.

FATE THERAPEUTICS' Chief Financial Officer, Kamal Adawi, was granted 75,000 restricted stock units and options to purchase 375,000 shares of common stock.

FATE Therapeutics' Chief Legal and Compliance Officer, Cindy Tahl, sold 9,037 shares of common stock to cover tax obligations related to RSU vesting.

FATE Therapeutics' President and CEO, Bahram Valamehr, sold 14,466 shares of common stock to cover tax withholding obligations related to RSU vesting.

Fate Therapeutics, Inc. has reported that Director Shefali Agarwal was granted 55,000 stock options with an exercise price of $1.32, as part of the company's non-employee director compensation policy.

FATE Therapeutics Inc. director Michael Lee was granted 55,000 stock options with an exercise price of $1.32, vesting by May 2026, as compensation for his board service and held on behalf of Redmile Group, LLC.

Redmile Group, LLC, a significant shareholder and director of FATE THERAPEUTICS INC, has reported the acquisition of 55,000 stock options for common stock at an exercise price of $1.32, granted in connection with Michael Lee's board service.

Fate Therapeutics, Inc. Director Yuan Xu was granted 55,000 stock options with an exercise price of $1.32 per share, as part of the company's non-employee director compensation policy.